Low Health Literacy Prevalence's Study in Patients With Chronic Cardiovascular Disease
NCT ID: NCT03952013
Last Updated: 2022-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2019-07-19
2020-12-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
An association has been shown between low HL and poorer health outcomes such as increased number of unscheduled hospitalisation or emergency visits, low medication adherence and poor health status.
These have been particularly demonstrated with cardiovascular diseases, which combine risk factors (emergency hospitalization, reduction in the length of hospital stays, and complex secondary preventive drug treatments). Despite large scientific international literature about HL and health outcomes, no information is available in France on the prevalence of low HL level among patients managed for neuro-cardio-vascular diseases.
It has been shown in other countries that healthcare professionals overestimate the HL level of their patients and do not adapt information to the HL level. Therefore, patients with low HL do not understand and/or are not able to use properly the information they receive.
Having a better knowledge of HL level and characteristics in these patients is necessary to develop tools for helping healthcare professionals to identify patients with low HL level and to realize the role of HL as a determinant of health. It will also provide more precise information on the difficulties or needs of patients with different levels of health literacy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Health Literacy in Adults With Congenital Heart Disease
NCT03170024
Cardiovascular Disease Knowledge/Morbidity--Socioeconomic Cohort Outcomes
NCT00005480
What Are the Factors for Maintaining and Stopping of Accompanying Citizens? Do Personality Traits of Accompanying Citizens Appear to Influence These Factors?
NCT05080517
Socioeconomic Deprivation and Peripheral Arterial Disease
NCT03693053
PREdisposition Genetical in Cardiac Insufficiency = Genetic Predisposition to Heart Failure
NCT01113268
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
All eligible patients included into one of the three existing cohorts studies of Hospices Civils de Lyon's hospitals: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE
* LOOP-HF (Registry of Congestive Heart Failure, NCT03422991),
* HIBISCUS-STEMI (Prospective cohort with a heart attack from ST segment elevation myocardium admitted to the centre coronary angiography room participating investigators, NCT03070496)
* HIBISCUS-STROKE (Prospective cohort of Stroke patients, NCT03149705)
To explore health literacy levels in patients hospitalized for acute neuro-cardiovascular diseases i.e. stroke, myocardial infarction, or heart failure
All patients included and followed within one of the three cohorts studies: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE who accepted to participate in the study, will be contacted by phone (attempted calls are set to 3 to reach the patient), mail or during a consultation, to answer to a health literacy questionnaire. The patient will participate in the study only once. The estimated duration is therefore estimated at 1 day for each patient and two month for the study. Thanks to the many following periods within the cohorts (6 months, 1 year and 18 month), we will measure health literacy at different times of the care.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
To explore health literacy levels in patients hospitalized for acute neuro-cardiovascular diseases i.e. stroke, myocardial infarction, or heart failure
All patients included and followed within one of the three cohorts studies: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE who accepted to participate in the study, will be contacted by phone (attempted calls are set to 3 to reach the patient), mail or during a consultation, to answer to a health literacy questionnaire. The patient will participate in the study only once. The estimated duration is therefore estimated at 1 day for each patient and two month for the study. Thanks to the many following periods within the cohorts (6 months, 1 year and 18 month), we will measure health literacy at different times of the care.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Can be reached by phone (telephone numbers will be obtained through cohorts)
* Included in one of the 3 cohorts LOOP-HF (Heart Failure), HIBISCUS (stroke and myocardial infarction) with the following eligibility criteria:
LOOP-HF
* Patient with congestive heart failure confirmed after at the end of: Hospitalization for congestive cardiac decompensation, Follow-up for stable congestive heart failure in consultation with at least one episode of cardiac decompensation within the year
* NT-proBNP \> 500ng/l in the month before inclusion
* New York Heart Association (NYHA) ≥ 2
* Age \> 18 years old
* Signature informed consent
HIBISCUS-STROKE
* Age \> 18 years old
* Diagnosis of ischemic cerebral infarction confirmed by brain imaging
* Visible proximal occlusion on brain imaging (ACI or M1)
* Patient treated with thrombolysis and/or thrombectomy
* Signature of consent by the patient or family member
HIBISCUS-STEMI
* Age \> 18 years old
* STEMI diagnosis defined by an elevation of the ST segment ≥ 0.2 mV in 2 leads contiguous on a 12-lead ECG.
* Percutaneous coronary intervention (PCI)
* Obtaining informed and signed consent obtained or oral consent attested by a third party.
Exclusion Criteria
* Not speaking French
LOOP-HF
* Life expectancy \< 1 year
* Patient over 90 years of age
* Recent discovery of heart failure (\< 3 months) long-term assisted or cardiac transplant patient
* Inability to provide the patient with informed information
* Loss of autonomy, dementia, major dependence
* Lack of coverage by the social security system
HIBISCUS-STROKE
* Patients \> 50 km from Pierre Wertheimer Hospital (follow-up in Lyon impossible)
* Patient for whom H0 sampling is not possible (telemedicine)
* Patient with active or uncontrolled cancer.
* Stroke of unknown schedule
* Lack of coverage by a Social Security scheme
* Deprivation of civil rights (guardianship, guardianship, protection of justice)
HIBISCUS-STEMI
* Unconfirmed STEMI diagnosis in angiography
* Refusal to participate in the study or to sign the consent
* Inability to provide informed information about the subject
* Lack of coverage by a Social Security scheme
* Clear contraindication to magnetic resonance imaging (claustrophobia, pacemaker, defibrillator, renal failure, known allergy to a product of contrast...)
* Deprivation of civil rights (guardianship, guardianship, protection of justice)
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LIT-S
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.